$Moderna, Inc.(MRNA)$ , the global mRNA giant, has partnered with artificial intelligence (AI) company OpenAI to embed GPT across all aspects of the company's business, including legal, research, manufacturing, and commercialization.
But in this AI frenzy, collaborations between life sciences and AI often blur the lines between reality and hype. Let's dive deeper and see what's really cooking.
The partnership kicked off in 2023 with the launch of mChat, powered by OpenAI's API. So far, 80% of Moderna's employees are already using ChatGPT's iterations. They've even got over 750 customized GPTs running on their internal ecosystem. One notable example is the Dose ID GPT, helping researchers pinpoint the right vaccine dose for clinical trials.
Selecting the perfect vaccine dose? Sounds like a mundane task, but getting FDA approval for clinical trials? That's a whole different ballgame, requiring tons of manpower and time from various departments. So, if a computer can quickly do the paperwork using Moderna's internal data, it's a huge help!
Moderna is becoming an AI-assisted enterprise, but the benefits might take a while to reflect in their profits. AI can streamline daily tasks, but it won't directly boost sales or clinical trial success rates.
Still, Moderna plans to market 14 new vaccines in the near future. Once they hit the market, investors might notice that Moderna's R&D costs, SG&A, and COGS as a percentage of revenue are lower than competitors. That gives them a cost advantage in biopharmaceutical development, which will drive the stock price higher.
But for now, this AI hype is still just talk. Let's see what actually pans out!
Comments